Monthly Archives: January 2021

In a time-stratified, case-crossover study, exposure to both large and small particulate matter, as well as to nitrogen dioxide, was significantly associated with increased odds of death from myocardial infarction (MI). Investigators found "consistent evidence" that short-term exposure to particulate matter with an aerodynamic diameter of 2.5m or smaller (PM2.5), particulate matter with an aerodynamic diameter less than 10m (PM10), and nitrogen dioxide (NO2) was associated with increased risk for mortality from MI, they write. The study was published in the January26 issue of the Journal of the American College of Cardiology. Continue reading →

This article was originally published here Libyan J Med. 2021 Dec;16(1):1857525 Continue reading →

Databridgemarketresearch.com Present Global Post-Acute Myocardial Infarction Market Industry Trends and Forecast to 2027 new report to its research database. This Global Post-Acute Myocardial Infarction Market report is structured with the thorough market analysis carried out by a team of industry experts, dynamic analysts, skilful forecasters and well-informed researchers. Continue reading →

Increasing legalization and expanding medicinal use have led to a significant rise in global cannabis consumption. With this development, we have seen a growing number of case reports describing adverse cardiovascular events, specifically, cannabis-induced myocardial infarction (MI). Continue reading →

Global Myocardial Infarction Treatment Industry: with growing significant CAGR during 2021-2026 New Research Report on Myocardial Infarction Treatment Market which covers Market Overview, Future Economic Impact, Competition by Manufacturers, Supply (Production), and Consumption Analysis Understand the influence of COVID-19 on the Myocardial Infarction Treatment Market with our analysts monitoring the situation across the globe. Continue reading →

The 42-year-old ambulance driver, G. Continue reading →

The newly added research report on the Myocardial Infarction Drug market is a complete guide to understand various factors that play a crucial role in growth progression. The report is designed to aid the investment decisions and motivate crucial investment discretion for new businesses looking out for seamless market penetration. Report on Myocardial Infarction Drug Market is a comprehensive study that deals with the status and position globally and provides DROC analysis for changing competitive dynamics and different factors driving or restraining industry growth. Continue reading →

Patients with rheumatoid arthritis (RA) are at increased risk for ischemic and non-ischemic heart disease, secondary to subclinical pathological changes in heart muscle and in coronary vessels, according to a review published in Rheumatic & Musculoskeletal Diseases. Systemic inflammation is a risk factor for cardiovascular disease (CVD) and treatment with conventional and biologic antirheumatic medications may have a significant impact on cardiovascular (CV) outcomes.1 Previous studies have established RA is an independent risk factor for premature atherosclerosis and reported that patients with RA are at an increased risk for CV events and cardiac mortality, compared with the general population.2-4 Chronic systemic inflammation secondary to rheumatic diseases is an important contributor for the increased CV risk among patients with RA and is associated with arterial stiffness, lipid-salvage mechanisms, and destabilization of plaques.4 Disease activity significantly affects CV risk, as each period of increased joint disease activity is associated with a 7% increased CV risk, while a low disease activity reduces the CV risk.5,6 Several proinflammatory cytokines have been associated with inflammation in RA and with pathogenesis of heart disease, including tumor necrosis factor-alpha, interleukin (IL)-1, IL-6 and IL-17.1 While the contribution of inflammation to atherosclerosis and ischemic heart disease is well described, the mechanisms responsible for non-ischemic heart disease is less well understood. In addition to inflammation, traditional CV risk factors, including hypertension, diabetes, dyslipidemia, obesity, smoking, family history and physical inactivity, may be more common among patients with RA, compared with the general population.7 Patients with RA were found to be at increased risk for myocardial infarction, major CV events and all-cause mortality, regardless of the presence of coronary artery disease (CAD) Continue reading →